Corvus Pharmaceuticals Inc
CRVSHealthcare|Biotechnology|USA
$15.67
-0.53 (-3.27%)
Tangible Book
$2.86
Earnings Power
$2.59
Upcoming Data Readouts (2)
Jun 2027
Est. completion
P2Atopic Dermatitis
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395n=200
Nov 2027
Est. completion
P3Peripheral T-Cell Lymphoma, Not Otherwise Specified
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048n=150
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2026
P1
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
NCT03952078